We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 6 for:    iconic therapeutics
Previous Study | Return to List | Next Study

Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma

This study is currently recruiting participants.
Verified August 2017 by Iconic Therapeutics, Inc.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02771340
First Posted: May 13, 2016
Last Update Posted: August 15, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Iconic Therapeutics, Inc.
  Purpose
The purpose of this study is to evaluate the safety, tolerability, biological activity, pharmacokinetics and pharmacodynamic activity of single and repeated escalating intravitreal doses of ICON-1 in patients with primary uveal melanoma who are planned to undergo enucleation or brachytherapy of the affected eye.

Condition Intervention Phase
Uveal Melanoma Choroid Neoplasm Biological: ICON-1 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-label, Multicenter Study Evaluating the Safety and Tolerability, Biologic Activity, Pharmacodynamics, and Pharmacokinetics of Single and Repeated Escalating Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma Who Are Planned to Undergo Enucleation or Brachytherapy

Resource links provided by NLM:


Further study details as provided by Iconic Therapeutics, Inc.:

Primary Outcome Measures:
  • Occurrence of adverse events [ Time Frame: 30 days (plus or minus 5 days) after surgical procedure ]

Secondary Outcome Measures:
  • Changes in plasma levels of ICON-1 [ Time Frame: 1 day after last dose of ICON-1 ]
  • Change in best corrected visual acuity (BCVA) [ Time Frame: On or 1 day prior to surgical procedure day ]

Estimated Enrollment: 10
Study Start Date: May 2016
Estimated Study Completion Date: September 2017
Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ICON-1 0.3 mg Singe Dose
Patients will receive a single intravitreal dose of ICON-1 0.3 mg
Biological: ICON-1
Intravitreal injection of ICON-1
Other Name: human Immuno-conjugate 1
Experimental: ICON-1 0.3 mg Repeat Dosing
Patients will receive two intravitreal doses of ICON-1 0.3 mg, one week apart
Biological: ICON-1
Intravitreal injection of ICON-1
Other Name: human Immuno-conjugate 1
Experimental: ICON-1 0.6 mg Repeat Dosing
Patients will receive two intravitreal doses of ICON-1 0.6 mg, one week apart
Biological: ICON-1
Intravitreal injection of ICON-1
Other Name: human Immuno-conjugate 1

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males or females of any race at least 18 years of age
  • Clinical diagnosis of primary uveal melanoma involving the posterior uveal tract in the study eye
  • Planned enucleation or brachytherapy of the study eye due to uveal melanoma

Exclusion Criteria:

  • Uveal melanoma in the study eye originating in the anterior uveal tract (iris)
  • Hereditary or chronic hemorrhagic or coagulopathy conditions (i.e., hemophilia)
  • Woman who is pregnant or lactating
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02771340


Contacts
Contact: Iconic Therapeutics 650-437-1000 clinicaltrials@iconictherapeutics.com

Locations
United States, California
Recruiting
San Francisco, California, United States, 94109
United States, Colorado
Recruiting
Denver, Colorado, United States, 80401
United States, Kansas
Recruiting
Leawood, Kansas, United States, 66211
United States, Massachusetts
Recruiting
Boston, Massachusetts, United States, 02114
United States, Michigan
Recruiting
Grand Rapids, Michigan, United States, 49546
Recruiting
Royal Oak, Michigan, United States, 48073
United States, Oregon
Recruiting
Portland, Oregon, United States, 97239
United States, Pennsylvania
Recruiting
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Iconic Therapeutics, Inc.
Investigators
Study Director: Gabriela Burian, MD Iconic Therapeutics, Inc.
  More Information

Additional Information:
Responsible Party: Iconic Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT02771340     History of Changes
Other Study ID Numbers: IT-003
First Submitted: May 6, 2016
First Posted: May 13, 2016
Last Update Posted: August 15, 2017
Last Verified: August 2017

Additional relevant MeSH terms:
Melanoma
Uveal Neoplasms
Choroid Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Eye Neoplasms
Neoplasms by Site
Eye Diseases
Uveal Diseases
Choroid Diseases
Immunoconjugates
Immunologic Factors
Physiological Effects of Drugs